```html

Alzheimer Disease – Comprehensive Medical Guide

Overview

Alzheimer disease (AD) is a progressive neurodegenerative disorder that impairs memory, thinking, and behavior. It is the most common cause of dementia, accounting for 60‑80 % of cases worldwide.

• Who it affects: Most patients are 65 years or older, but early‑onset Alzheimer’s can appear between ages 30‑60.
• Prevalence: According to the World Health Organization (2023), about 55 million people live with dementia globally; roughly 32 million have Alzheimer’s. In the United States, the Alzheimer’s Association estimates 6.5 million Americans aged 65+ are living with AD, and the number is projected to rise to 13 million by 2050.
• Progression: The disease advances through mild, moderate, and severe stages over an average of 8‑10 years, though some individuals decline more quickly.

Symptoms

Symptoms evolve as the disease progresses. Below is a complete list with typical descriptions.

Mild (Early) Stage

• Memory loss for recent events: forgetting conversations, appointments, or where objects were placed.
• Difficulty finding words: pausing or using incorrect words (anomia).
• Disorientation: getting lost in familiar neighborhoods.
• Impaired judgment: difficulty making decisions about money or grooming.
• Changes in mood: increased anxiety, depression, or irritability.

Moderate (Middle) Stage

• Increased forgetting: difficulty recognizing close family members.
• Problems with complex tasks: managing finances, cooking, or driving.
• Behavioral changes: agitation, wandering, repetitive questioning.
• Sleep disturbances: daytime napping, nighttime awakening.
• Decline in language: reduced speech, use of gestures.

Severe (Late) Stage

• Severe memory loss: inability to recall personal history.
• Loss of basic functions: difficulty swallowing, incontinence.
• Extreme personality changes: aggression, delusions, paranoia.
• Physical decline: limited mobility, increased risk of infections.

Causes and Risk Factors

Underlying Pathology

• Beta‑amyloid plaques: abnormal protein fragments accumulate between neurons, disrupting communication.
• Neurofibrillary tangles: twisted tau proteins inside neurons impair nutrient transport.
• Neuronal loss & inflammation: chronic brain inflammation accelerates cell death.

Genetic Factors

• APP, PSEN1, PSEN2 mutations: cause early‑onset familial Alzheimer’s (<1 % of cases).
• APOE ε4 allele: the strongest known genetic risk for late‑onset AD; having one copy triples risk, two copies can increase it up to 15‑fold (NIH, 2022).

Non‑Genetic Risk Factors

• Age ≥ 65 (risk doubles every 5 years after 65).
• Family history of dementia.
• Cardiovascular disease, hypertension, diabetes, high cholesterol.
• Head trauma with loss of consciousness.
• Lifestyle factors: smoking, physical inactivity, low education, social isolation.
• Sleep apnea and chronic poor sleep.

Diagnosis

Diagnosis is clinical, supported by cognitive testing and brain imaging. No single test confirms AD.

Initial Evaluation

• Medical history & physical exam: assess symptom onset, comorbidities, medication review.
• Neuropsychological testing: Mini‑Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) to quantify cognitive deficits.

Laboratory Tests

• Blood work to rule out reversible causes (vitamin B12 deficiency, thyroid dysfunction, infections).
• Genetic testing for APOE ε4 or familial mutations when indicated.

Brain Imaging

• MRI: detects cortical atrophy, rules out strokes, tumors.
• CT scan: useful when MRI unavailable.
• PET scans:
  • FDG‑PET assesses glucose metabolism (hypometabolism in temporoparietal regions).
  • Amyloid PET (e.g., Florbetapir) visualizes amyloid burden; FDA‑approved for AD diagnosis.

Biomarkers (Emerging)

• CSF analysis for decreased Aβ42 and increased total/phosphorylated tau.
• Blood‑based biomarkers (plasma p‑tau181) are under validation and may become routine within the next few years (Nature Medicine, 2023).

Treatment Options

Pharmacologic Therapies

• Cholinesterase inhibitors: donepezil, rivastigmine, galantamine – modestly improve cognition and daily functioning in mild‑to‑moderate AD.
• NMDA‑receptor antagonist: memantine – used for moderate‑to‑severe disease; may improve attention and reduce behavioral symptoms.
• Disease‑modifying agents (investigational): monoclonal antibodies targeting amyloid (aducanumab, lecanemab, donanemab). Lecanemab received FDA approval (2023) for early AD with confirmed amyloid pathology; monitoring for ARIA (amyloid‑related imaging abnormalities) is essential.
• Symptom‑targeted meds: antidepressants, antipsychotics (only for severe agitation, used with caution), sleep aids.

Non‑Pharmacologic Interventions

• Regular aerobic exercise (150 min/week) improves cerebral blood flow and slows cognitive decline.
• Cognitive stimulation therapy and structured mental activities (e.g., puzzles, music) enhance neural plasticity.
• Sleep hygiene and treatment of sleep apnea.
• Dietary approaches: Mediterranean or MIND diet (high in leafy greens, berries, fish, olive oil) linked to reduced AD risk.

Procedural & Supportive Care

• Occupational therapy for adaptive equipment and safety modifications.
• Speech‑language therapy for communication difficulties.
• Advanced care planning – legal documents, power of attorney, and end‑of‑life preferences.

Living with Alzheimer Disease

Daily Management Tips

• Establish routines: consistent wake‑up, meals, and bedtime reduce confusion.
• Use visual cues: labeled drawers, calendars, reminder notes.
• Safety-proof the home: remove tripping hazards, install grab bars, use stove timers.
• Maintain social engagement: regular visits with friends/family, community groups, or virtual meet‑ups.
• Monitor nutrition and hydration: small, frequent meals; offer fluids often.
• Plan for transportation: arrange rides or use ride‑share services as driving ability declines.
• Caregiver support: respite care, support groups, and counseling to prevent burnout.

Legal & Financial Planning

Early in the disease, create or update:

• Durable Power of Attorney for health care.
• Financial Power of Attorney.
• Living will or advance directive.
• Review insurance coverage (Medicare, long‑term care).

Prevention

While no method guarantees prevention, research identifies modifiable factors that lower risk.

• Physical activity: at least 150 minutes of moderate‑intensity aerobic exercise per week (CDC, 2022).
• Cognitive engagement: lifelong learning, playing musical instruments, bilingualism.
• Cardiovascular health: control blood pressure, cholesterol, and diabetes.
• Healthy diet: Mediterranean or MIND diet rich in antioxidants and omega‑3 fatty acids.
• Social interaction: regular contact with friends, volunteering, group activities.
• Sleep: 7‑8 hours of quality sleep; treat sleep apnea.
• Avoid tobacco & limit alcohol: smoking cessation lowers vascular contributions; moderate alcohol (if any) is advised.

Complications

If Alzheimer’s progresses without adequate management, several serious complications can arise:

• Severe malnutrition & dehydration: due to forgetting to eat or difficulty swallowing.
• Falls and fractures: impaired balance and judgment increase injury risk.
• Infections: urinary tract infections, pneumonia (especially aspiration pneumonia).
• Pressure ulcers: from reduced mobility.
• Psychiatric issues: severe depression, anxiety, or psychosis.
• Legal & financial crises: exploitation, unplanned medical expenses.

When to Seek Emergency Care

References

• World Health Organization. Dementia Fact Sheet, 2023.
• Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures.
• Mayo Clinic. Alzheimer's disease, accessed May 2026.
• National Institute on Aging (NIH). Alzheimer’s Disease Genetics, 2022.
• Cleveland Clinic. Diagnostic tests for Alzheimer’s disease, 2023.
• Nature Medicine. “Blood plasma p‑tau181 as a biomarker for Alzheimer’s disease,” 2023.
• U.S. Centers for Disease Control and Prevention. Physical Activity and Brain Health, 2022.

```